Image

PRP Versus HA IN OSTEOARTHRITIS OF THE PATELLOFEMORAL JOINT

Recruiting
30 - 65 years of age
Both
Phase N/A

Powered by AI

Overview

The aim of the study is to compare the 12-month clinical outcomes of patients with patellofemoral osteoarthritis undergoing infiltrative treatment with fresh PRP and HA

Description

166 patients affected by patellofemoral osteoarthritis will be included in a double-blinded RCT. In this study one group of patients will be treated with 1 intra-articular injection of PRP (treatment arm) and one group will be treated with 1 intra-articular injection of HA (control arm). Patients will be followed-up with clinical evaluation at baseline and at 2.6.12 and 24 months. Questionnaires will be administered for clinical evaluations during the follow-up visits.

Eligibility

Inclusion Criteria:

  1. Age between 30 and 65;
  2. Signs and symptoms of isolated patellofemoral osteoarthritis present in one or both knees;
  3. Radiographic signs of isolated patellofemoral osteoarthritis (according to Iwano et al stage 1-3 classification) or chondropathy (assessed on MRI) with K-L grade of the other compartments ≤ 2. [PMID: 2302884 - PMID: 27979409] ;
  4. Hemoglobin > 11 g/dl; Platelet count > 150,000 plt/mm3 (Recently performed CBC exam);
  5. No clinically significant electrocardiographic alterations (Recently performed ECG).
  6. Ability and consent of patients to actively participate in clinical follow-up;
  7. Signature of informed consent.

Exclusion Criteria:

  1. Patients unable to express consent;
  2. Patients who have undergone intra-articular infiltration of another substance within the previous 6 months;
  3. Patients undergoing knee surgery within the previous 12 months;
  4. Patients with malignant neoplasms;
  5. Patients with rheumatic diseases;
  6. Patients with diabetes;
  7. Patients with hematologic diseases (coagulopathies);
  8. Patients on anticoagulant-antiaggregant therapy;
  9. Patients with thyroid metabolic disorders;
  10. Patients abusing alcoholic beverages, drugs or medications;
  11. Body Mass Index > 35;
  12. Patients who have taken NSAIDs in the 3 days prior to blood draw;
  13. Patients with cardiovascular disease for which a 60 mL blood draw would be contraindicated;
  14. Patients with a recently performed blood test with Hb< 11 g/dl and Platelets < 150,000 plt/mm3.
  15. Previous treatment of patellar dislocation
  16. Iwano score of grade 4.

Study details

Patellofemoral Osteoarthritis

NCT04937998

Istituto Ortopedico Rizzoli

22 May 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.